For decades, pregnant women have remained one of the most systematically excluded populations in pre-approval clinical development programs. As a result, many therapeutics enter the market with limited or no human pregnancy safety data despite anticipated real-world exposure shortly after commercialization. FDA’s May 2026 guidance, Postapproval Pregnancy Safety Studies, represents a significant evolution in regulatory expectations for pregnancy pharmacovigilance and real-world evidence generation. The guidance outlines how sponsors should operationalize pregnancy registries, observational epidemiology programs, and complementary data strategies to characterize maternal, fetal, and infant risk profiles in the postmarketing setting. For regulatory affairs, pharmacovigilance, and clinical operations professionals, this document signals a growing expectation that lifecycle safety surveillance must compensate for persistent evidence deficits created during premarket development.
The new FDA guidance providing a comprehensive framework for the design and execution of postmarketing investigations evaluating drug and biologic exposure during pregnancy. The guidance reflects FDA’s increasing emphasis on real-world evidence (RWE), structured pharmacovigilance, and longitudinal maternal-fetal safety assessment across the product lifecycle.
The guidance acknowledges a longstanding industry reality: pregnant women are routinely excluded from interventional clinical trials, resulting in substantial uncertainty regarding fetal, maternal, and neonatal safety at the time of approval. FDA explicitly recognizes that this historical exclusion shifts risk characterization into the postmarketing environment, where broader exposure occurs under routine clinical practice conditions.
Central to the guidance is FDA’s endorsement of three complementary evidence-generation paradigms: Case reports and case series, prospective pregnancy registries, and complementary observational studies using electronic healthcare data, surveillance systems, and case-control methodologies. FDA emphasizes that these approaches should not be interpreted hierarchically but rather as integrated pharmacovigilance tools contributing collectively to benefit-risk assessment and product labeling updates.
Pregnancy registries receive the most extensive operational treatment within the guidance. FDA characterizes registries as prospective observational real-world data platforms capable of collecting granular exposure, outcome, and covariate information before pregnancy outcomes are known, thereby reducing recall bias and exposure misclassification. The Agency strongly recommends predefined protocols, feasibility assessments, comparator selection strategies, statistical analysis plans, retention programs, and independent scientific oversight committees.
Importantly, FDA recognizes that single-product pregnancy registries frequently suffer from low enrollment, inadequate statistical power, and significant loss to follow-up. To address these limitations, the guidance encourages multiproduct and disease-based registries, particularly for therapeutic areas such as autoimmune disorders, epilepsy, or HIV, where shared infrastructure can improve enrollment efficiency and provide clinically meaningful comparator cohorts.
The guidance also strongly reinforces the role of complementary RWE methodologies. FDA highlights the growing utility of electronic health records (EHRs), administrative claims databases, birth defect surveillance networks, and mother-infant linkage systems for large-scale pharmacoepidemiologic analyses. Sponsors are expected to demonstrate methodological rigor regarding gestational age estimation, exposure ascertainment, outcome validation, confounder adjustment, and mitigation of live-birth bias.
From a regulatory science perspective, the guidance is both pragmatic and overdue. FDA appropriately acknowledges that robust pregnancy safety characterization often cannot be achieved pre-approval under current clinical development paradigms. However, the document simultaneously exposes a structural weakness in modern drug development: the industry continues to rely heavily on postmarketing evidence generation because pregnant women remain largely excluded from pivotal clinical trials. This creates a profound evidence paradox. Drugs are frequently prescribed during pregnancy for chronic diseases, acute infections, autoimmune disorders, psychiatric conditions, and public health emergencies despite limited human safety data at launch. FDA itself notes that approximately 41.6% of pregnancies in the United States are unintended, increasing the likelihood of inadvertent fetal exposure before pregnancy recognition. Consequently, the burden of safety characterization shifts downstream into observational research environments inherently vulnerable to confounding, incomplete data capture, recruitment failures, and exposure misclassification.
While the guidance substantially improves operational expectations for postapproval surveillance, it does not fundamentally resolve the upstream exclusion problem. Pregnancy registries and retrospective database analyses are valuable tools, but they are imperfect substitutes for controlled clinical evidence. Many registries fail to achieve adequate enrollment or statistical power, particularly for rare exposures and rare congenital malformations. Additionally, observational designs remain susceptible to confounding by indication, selection bias, and incomplete ascertainment of non-live birth outcomes.
The broader regulatory challenge moving forward will be determining how to responsibly increase inclusion of pregnant women in earlier phases of clinical development while maintaining appropriate fetal safeguards. Until that paradigm evolves, postmarketing pregnancy safety programs will remain essential components of lifecycle benefit-risk management and labeling optimization. For regulatory affairs and clinical operations leaders, sponsors are expected to implement proactive, protocol-driven, scientifically rigorous evidence-generation ecosystems capable of informing labeling, supporting regulatory commitments, and strengthening maternal-fetal safety decision-making throughout commercialization.
FDA’s 2026 pregnancy safety guidance represents a significant maturation of the Agency’s expectations for lifecycle pharmacovigilance and real-world evidence generation. The document provides sponsors with a detailed operational blueprint for developing scientifically credible pregnancy safety datasets capable of informing regulatory decision-making and product labeling. At the same time, the guidance underscores a persistent systemic issue within drug development: pregnant women continue to enter the postmarketing environment with insufficient pre-approval safety characterization. As regulators increasingly rely on observational methodologies to close this evidence gap, sponsors will need stronger epidemiologic infrastructure, advanced RWE capabilities, and more integrated safety surveillance strategies. Ultimately, the guidance is not merely about compliance, it is about building a more evidence-informed framework for maternal-fetal therapeutics in modern regulatory science.
